Neurogene
NGNE
23 hedge funds and large institutions have $59.6M invested in Neurogene in 2014 Q1 according to their latest regulatory filings, with 23 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$15.6M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$7.75M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.56M |
| 4 |
BC
Broadfin Capital
New York
|
+$6.56M |
| 5 |
VAM
Visium Asset Management
New York
|
+$3.84M |
Top Sellers
NGNE Hedge Fund Activity: Q1 2014 in Review
23 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q1 2014, worth a combined $59.6M.
Buyers outnumbered sellers: 23 funds opened new NGNE positions and 0 closed out — a net gain of 23 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $15.6M.
- 23 institutional investors held Neurogene (NGNE) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $59.6M of Neurogene stock for Q1 2014.
- 23 funds opened new Neurogene positions in Q1 2014 and 0 closed out, a net change of +23 holders.
- The largest Neurogene buyer in Q1 2014 was Baker Bros. Advisors, an estimated $15.6M added.
Based on aggregated 13F filings for Q1 2014.